FDA Establishes Controls on Polymorphic Substances
This article was originally published in The Gold Sheet
Polymorphic guidance addresses need to control multi-form drugs.
You may also be interested in...
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.
Criticized for giving foreign sites advance notice of inspections, agency is considering giving such notice to domestic sites too even after surprise inspections become possible.